These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 23687087)
21. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study. Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632 [TBL] [Abstract][Full Text] [Related]
26. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Parikh C; Subrahmanyam R; Ren R Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213 [TBL] [Abstract][Full Text] [Related]
27. MEK1 is required for the development of NRAS-driven leukemia. Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509 [TBL] [Abstract][Full Text] [Related]
28. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Lee BH; Tothova Z; Levine RL; Anderson K; Buza-Vidas N; Cullen DE; McDowell EP; Adelsperger J; Fröhling S; Huntly BJ; Beran M; Jacobsen SE; Gilliland DG Cancer Cell; 2007 Oct; 12(4):367-80. PubMed ID: 17936561 [TBL] [Abstract][Full Text] [Related]
29. Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Caraffini V; Geiger O; Rosenberger A; Hatzl S; Perfler B; Berg JL; Lim C; Strobl H; Kashofer K; Schauer S; Beham-Schmid C; Hoefler G; Geissler K; Quehenberger F; Kolch W; Athineos D; Blyth K; Wölfler A; Sill H; Zebisch A Haematologica; 2020; 105(2):375-386. PubMed ID: 31097632 [No Abstract] [Full Text] [Related]
30. Anti-leukemic effects of simvastatin on NRAS Jang J; Lee J; Jang JH; Jung CW; Park S Mol Biol Rep; 2019 Dec; 46(6):5859-5866. PubMed ID: 31452046 [TBL] [Abstract][Full Text] [Related]
31. Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo. Wang T; Li C; Xia C; Dong Y; Yang D; Geng Y; Cai J; Zhang J; Zhang X; Wang J Am J Transl Res; 2015; 7(10):1963-73. PubMed ID: 26692939 [TBL] [Abstract][Full Text] [Related]
32. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways. Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279 [TBL] [Abstract][Full Text] [Related]
33. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis. Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865 [TBL] [Abstract][Full Text] [Related]
34. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934 [TBL] [Abstract][Full Text] [Related]
36. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters. Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187 [TBL] [Abstract][Full Text] [Related]
37. GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice. Harada N; Hasegawa A; Hirano I; Yamamoto M; Shimizu R Cancer Sci; 2019 Apr; 110(4):1183-1193. PubMed ID: 30710465 [TBL] [Abstract][Full Text] [Related]
38. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678 [TBL] [Abstract][Full Text] [Related]
39. Adaptive endoplasmic reticulum stress signalling via IRE1α-XBP1 preserves self-renewal of haematopoietic and pre-leukaemic stem cells. Liu L; Zhao M; Jin X; Ney G; Yang KB; Peng F; Cao J; Iwawaki T; Del Valle J; Chen X; Li Q Nat Cell Biol; 2019 Mar; 21(3):328-337. PubMed ID: 30778220 [TBL] [Abstract][Full Text] [Related]
40. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]